Bisacodyl
Basic Information
| Item | Value |
|---|---|
| DrugBank ID | DB09020 |
| Evidence Level | L5 (Computational Prediction) |
| Number of Predicted Indications | 20 |
Predicted Indications (TxGNN)
The following are potential new indications predicted by the TxGNN model. Higher scores indicate higher predicted relevance.
| # | Indication | Source |
|---|---|---|
| 1 | exercise-induced malignant hyperthermia | KG + DL |
| 2 | dyspepsia | KG + DL |
| 3 | nephrogenic syndrome of inappropriate antidiuresis | KG + DL |
| 4 | malignant hyperthermia, susceptibility to | KG + DL |
| 5 | common cold | KG + DL |
| 6 | pharyngitis | KG + DL |
| 7 | familial periodic paralysis | KG + DL |
| 8 | acute laryngopharyngitis | KG + DL |
| 9 | malignant hyperthermia of anesthesia | KG + DL |
| 10 | acute pulmonary heart disease | KG + DL |
| 11 | X-linked centronuclear myopathy | KG + DL |
| 12 | King-Denborough syndrome | KG + DL |
| 13 | gastroparesis (disease) | KG + DL |
| 14 | nasal cavity disease | KG + DL |
| 15 | hypokalemic periodic paralysis | KG + DL |
| 16 | moderate multiminicore disease with hand involvement | KG + DL |
| 17 | central core myopathy | KG + DL |
| 18 | congenital multicore myopathy with external ophthalmoplegia | KG + DL |
| 19 | thyrotoxic periodic paralysis, susceptibility to | KG + DL |
| 20 | HELIX syndrome | KG + DL |
Disclaimer
These predictions are for research purposes only and do not constitute medical advice. Clinical validation is required before any clinical application.